Navigation Links
SemBioSys initiates toxicology study for safflower-produced insulin
Date:3/26/2008

Initiation of study puts company on track for Phase I/II trial

TSX symbol: SBS

CALGARY, March 26 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has initiated a toxicology study in animals to demonstrate the safety and comparability of its safflower-produced insulin to pharmaceutical grade human insulin. This study is a final key step in the Company's preparations to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the third quarter in order to initiate a Phase I/II human clinical trial this year. The 28-day repeat dose study in monkeys and rats is the only toxicology study required before submission of the IND application to the FDA. The study is also a required component for the abbreviated 505(b)(2) application process that SemBioSys is eligible to follow, based on the well-characterized nature of insulin. The study aims to establish that the toxicology profile of insulin produced from SemBioSys' plant system is appropriate to begin human trials.

"Insulin is currently one of the largest volume recombinant biopharmaceutical products on the market and demand is projected to increase dramatically in the coming years. The scalability of our safflower-produced insulin has the potential to provide a cost-effective source of insulin to meet this growing demand," said Andrew Baum, President and CEO of SemBioSys. "In order to start the toxicology study we had to demonstrate that our safflower-produced insulin is chemically, physically and structurally equivalent to human insulin using a broad array of assays. The toxicology study is an important milestone for our insulin program and demonstrates that we are on track to begin human clinical trials in the second half of 2008."

SemBioSys has already established
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys announces 2007 financial and operational results
2. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
3. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
4. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
5. SemBioSys signs option agreement for safflower-produced food ingredient
6. SemBioSys announces 2007 third quarter results
7. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
8. SemBioSys updates Apo AI development program
9. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
10. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
(Date:8/26/2014)... what they believe is the thinnest-possible semiconductor, a ... only three atoms thick. , The University of ... single-layer semiconductor materials can be connected in an ... result could be the basis for next-generation flexible ... and solar technologies. , "Heterojunctions are fundamental elements ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2
... article profiling the significant rise in valuation of ... is true product innovation through focused R&D efforts that's currently ... valuation. , ,While Genentech had revenues of $4.6 billion in ... ,This surpasses Amgen's top position of $72.2 billion, is pretty ...
... and the Endpoint Exchange Network said on Tuesday ... be able to exchange check data and images, starting with ... an IT service provider claiming 4,000 financial clients. Endpoint Exchange ... Metavante , the technology arm of Marshall & Ilsley ...
... Corp. said on Wednesday it has agreed to buy ... spinoff, for $600 million in cash. , ,Bone Care and ... $2 billion and almost 7,000 employees worldwide, plan to complete ... reported healthy quarterly profits and revenues. Bone Care tallied its ...
Cached Biology Technology:Drug innovation beats marketing, patents and mergers 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:8/27/2014)... evidence puts into doubt the long-standing belief that a ... brain plays a central role in depression. In ... that mice lacking the ability to make serotonin in ... conventional wisdom) did not show depression-like symptoms. , ... VA Medical Center and Wayne State University School of ...
(Date:8/27/2014)... Now that health advocates, campaigns against trans-fats have ... additive, they,re taking aim at sugar for its ... and policymakers are still wrangling over the best ... according to an article in Chemical & ... of the American Chemical Society. , In the ...
(Date:8/27/2014)... can be weaned later with no negative effects on ... at the University,s Roseworthy campus, published in the journal ... for pig producers. It allows improvements in piglet health ... usually start their oestrous cycles again during lactation, only ... says Ms Alice Weaver, PhD candidate with the School ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... BEER-SHEVA, ISRAEL -- July 28, 2009 A study conducted ... John Hopkins Bloomberg School of Public Health indicates that approximately ... for work in a pandemic flu emergency, regardless of the ... PLOS ONE , as conducted among 1,835 public health ...
... The area of forest burnt by wildfires in the United ... to research by climate scientists. The study predicts that ... Northwest and the Rocky Mountains, where the area of forest destroyed ... The research is based on a conservative temperature increase of ...
... July 28, 2009 A St. Louis-based team of ... malnutrition throughout the developing world today announced the ... humanitarian effort involving St. Louis Children,s Hospital, The ... School of Medicine. Though they share a ...
Cached Biology News:1 in 6 health workers won't report in flu pandemic -- study by Ben-Gurion U. researchers 21 in 6 health workers won't report in flu pandemic -- study by Ben-Gurion U. researchers 3Wildfires set to increase 50 percent by 2050 2Researchers team up to provide new hope for childhood hunger 2Researchers team up to provide new hope for childhood hunger 3Researchers team up to provide new hope for childhood hunger 4
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... stains proteins in polyacrylamide gel after ... 8 ng of protein) with *CoomassieR-G250. ... processes can be performed in 1.5 ... min), proteins can be seen before ...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
Biology Products: